Charles River Laboratories International, Inc.’s Stock Price Skyrockets to $106.60, Showcasing a Stellar 6.87% Increase

Charles River Laboratories International, Inc. (CRL)

106.60 USD +6.85 (+6.87%) Volume: 3.99M

Charles River Laboratories International, Inc.’s stock price has seen a significant rise in today’s trading session, surging by +6.87% to reach 106.60 USD, driven by a high trading volume of 3.99M. However, CRL’s stock performance has been on a downward trend YTD, reflecting a -42.25% decrease, indicating a volatile market for the global provider of products and services to pharmaceutical and biotechnology companies.

Latest developments on Charles River Laboratories International, Inc.

Today, Charles River Laboratories International Inc. stock stood out from its competitors with a strong trading day. Despite challenges in the life sciences sector leading to a reduced price target by TD Cowen, the company’s stock performance remained robust. TD Cowen adjusted Charles River Laboratories International’s price target to $105 from $179 while maintaining a hold rating. Additionally, the company faced setbacks as it was hit by the FDA, causing uncertainty about a potential comeback. These events have contributed to fluctuations in Charles River Laboratories‘ stock price movements today.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. has a positive long-term outlook based on its Smartkarma Smart Scores. With a high value score of 4, the company is considered to be a good investment in terms of its current stock price compared to its intrinsic value. However, its low dividend score of 1 may deter income-seeking investors. In terms of growth and resilience, Charles River Laboratories scored a 2 and 3 respectively, indicating moderate potential for future growth and a good ability to withstand economic downturns. The company also scored a 3 in momentum, suggesting that it is showing steady performance in the market.

As a provider of research tools and support services for drug discovery and development, Charles River Laboratories serves a wide range of customers in the pharmaceutical and biotechnology industries, as well as hospitals and academic institutions. With its Smartkarma Smart Scores reflecting a solid value, resilience, and momentum, the company appears to be well-positioned for long-term success in the competitive market of research and development services for new drugs, devices, and therapies.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma